Business Wire

European Banana Market: Afruibana Look to the Future

26.4.2021 14:09:00 EEST | Business Wire | Press release

Share

At a webinar with African and European decision-makers, Afruibana, the association of African banana producers, presented the African Banana White Paper entitled: "Bananas at the heart of African rural development a common challenge for Africa and Europe".

The launch is supported by MEP Marie-Pierre Vedrenne, Vice-Chair of the Committee on International Trade, MEP Pierrette Herzberger-Fofana, Vice-Chair of the Committee on Development, and by Carlos Zorrinho, Co-Chair of the ACP-EU Joint Parliamentary Assembly.

Make the African banana more competitive and sustainable

The White Paper charts five fields of investment as priorities: human capital and territorial development, R&D and modernisation of cultivation practices, change of agricultural model for better productivity, ecological and energy transition, local processing and development of regional markets.

All these solutions aim at improving the sector's carbon footprint and are part of the "farm to fork" approach to sustainable food production, where the use of synthetic products is systematically limited as much as possible.

A depressed European banana market

While in 2013 Dollar bananas already accounted for 69.1% of the European market, the sharp build up in their production capacities, combined with deregulation and an increase of supermarkets bargaining power have jointly led to a massive growth in their relative market shares, now standing at 75.5%. Over the same period (2013-2020), despite considerable efforts to improve competitiveness, African producers saw their market share fall from 10.1% to 8.9%, that of Caribbean producers in the ACP area from 9.5% to 6.8% while that of European producers slid from 11.3% to 8.9%.

While exported volumes of bananas to the European Union increased, this glut has led to a significant drop in price. Whereas, in 2015, the average import price was 14.3 euros/carton of bananas, in 2020, it dropped to 11.7 euros, thereby seriously jeopardising all origins, even Latin Americans.

Post-Cotonou, an opportunity for a new start between Africa and Europe

“The integration of the Sustainable Development Goals (SDGs) in the post-Cotonou agreement is a good thing, but it must be accompanied by some political coherence on the European side” explains Joseph Owona Kono, president of Afruibana. “Between the stated objectives of the EU's development policy and the practices of its trade policy, there must be consistency and harmonisation, in order to preserve the sectors that create wealth and jobs on the African continent”.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Léonard Lifar
ll@35nord.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release

NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release

Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release

IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye